Bruce Ewenstein
8Patents
1h-index
11Co-inventors
44Inventor score
Filing activity: Jun 11, 2012 → Dec 6, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9272021B2 | Treatment of coagulation disease by administration of recombinant VWF | Human Necessities | 5 | Active |
| US12016904B2 | Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF | Human Necessities | 1 | Active |
| US10905746B2 | Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF | Human Necessities | 1 | Active |
| US10632176B2 | Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF | Human Necessities | 1 | Active |
| US11529395B2 | Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF | Human Necessities | 1 | Active |
| US11191818B2 | Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome | Human Necessities | 0 | Active |
| US12156903B2 | Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome | Human Necessities | 0 | Active |
| US12128090B2 | Methods of prophylactic treatment using recombinant VWF (rVWF) | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.